The Pharma Data

MARCH 16, 2022

using SNAP-tag) involves labeling cell proteins with a fluorescent dye, thereby enabling researchers to observe how proteins interact in the living cell and where in the cell they are located. With Spirochrome, he commercialized fluorescent probes for cell biology, while with Covalys, he marketed SNAP-tag and other protein labeling methods.

Protein 52

Protein Scientist Gene Development 52

pharmaphorum

APRIL 26, 2021

The initiative was supported by grants from UCB and Pfizer and provided health information in the form of immersive experiences aimed at patients prescribed biologic drugs to treat the disease. The company halted development before it eventually sold its digital health unit back to Eric Careel, co-founder of Withings, the following year.

Development 121

Development Medicine Production Marketing 121

The Pharma Data

JANUARY 31, 2021

Utilizing Clover’s proprietary Trimer-Tag© technology, S-Trimer is a trimeric SARS-CoV-2 spike (S)-protein subunit vaccine candidate. About Trimer-Tag© Technology. Trimer-Tag© is an innovative drug development platform which allows the production of novel, covalently-trimerized fusion proteins. —- End —-.

Clinical Trials 52

Clinical Trials Clinical Trials Vaccination Vaccine 52

Pharmaceutical Technology

APRIL 5, 2023

But access to these treatments continues to remain limited due to high price tags and variable availability across regions. Across the world, to varying degrees, the regulations were written in an era of small molecules and biologics. But there is that significant challenge. There has been extremely rapid progress.

Gene Therapy 147

Gene Therapy Gene Engineer Production 147

The Pharma Data

NOVEMBER 15, 2020

Peng Liang , Founder and Chief Scientific Officer of Clover and inventor of the Trimer-Tag© technology, says, “A successful vaccine that can truly modulate the course of the COVID-19 pandemic must have four essential characteristics: safety, efficacy, scalability of manufacturing, and speed. About Cytiva.

Vaccination 52

Vaccination Vaccine Manufacturing Life Science 52

Rethinking Clinical Trials

AUGUST 18, 2022

-If we accept and acknowledge that race is a social construct, not a category that is tied to biological or genetic differences, then what does that mean when we see clear differences and disparities in health outcomes for these populations? There is plenty of data that shows that. Passitonstudy.org/results. New Ideas study.

Clinical Trials 130

Clinical Trials Clinical Trials Trials Insulin 130

Rethinking Clinical Trials

AUGUST 3, 2023

Tags #pctGR, @Collaboratory1 The post Grand Rounds July 28, 2023: How Can Researchers Fight Misinformation About Medicine?    Speaker Carl T. As researchers, we are producers and consumers of the medical literature. It is important to know and understand the information landscape into which your research is going out.

Medicine 130

Medicine Research Vaccination Vaccine 130

Drug Discovery World

FEBRUARY 21, 2023

How can you track and tag information so that when someone looks at it a week later or three years later, the data still makes sense?” Ashwin Pillai is Test Engineer 3 in HTS & Assay Development at Ginkgo Bioworks, a company whose mission is to make biology easier to engineer. There is also an issue with metadata during experiments.

Scientist 52

Scientist Gene Editing Engineer Bioinformatics 52

The Pharma Data

DECEMBER 3, 2020

Utilizing Clover’s proprietary Trimer-Tag © technology, S-Trimer is a trimeric SARS-CoV-2 spike (S)-protein subunit vaccine candidate. About Trimer-Tag © Technology. Trimer-Tag © is an innovative drug development platform which allows the production of novel, covalently-trimerized fusion proteins. 4, 2020 08:00 UTC.

Vaccination 52

Vaccination Vaccine Immune Response Protein 52

Drug Discovery World

NOVEMBER 13, 2023

Ahead of protein and antibody engineering conference PEGS Europe 2024 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting. Yuchih Lin, Doctor, Sino Biological Europe, on: ‘Accelerating drug discovery using advanced antibody development platforms’.

Protein 59

Protein Antibody Engineer Scientist 59

Drug Discovery World

NOVEMBER 9, 2023

Ahead of protein and antibody engineering conference PEGS Europe 2024 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting. Kielczewska will present: ‘Discovery of antibody-based therapeutics to challenging targets: Platform considerations’.

Engineer 52

Engineer Antibody Protein In-Vivo 52

Drug Discovery World

NOVEMBER 7, 2022

Cereblon, the researchers determined, has a default ‘open’ conformation, but must be switched to a particular ‘closed’ conformation for the ubiquitin-tagging of target proteins. . The structural data revealed that CELMoDs must bind to cereblon in a way that changes its shape, or conformation.

Scientist 52

Scientist Drugs Protein Research 52

XTalks

AUGUST 19, 2022

Zynteglo’s hefty price tag of $2.8 Today’s approval is an important advance in the treatment of beta-thalassemia, particularly in individuals who require ongoing red blood cell transfusions,” said Peter Marks, MD, PhD, director of the FDA’s Center for Biologics Evaluation and Research in the FDA press announcement for Zynteglo’s approval.

Gene Therapy 95

Gene Therapy FDA Approval Gene Clinical Trials 95

Drug Discovery World

JANUARY 10, 2023

Pillar 4: Biological Characteristics. Pillar 5: Protein OE/Epitope Tags. Nat Methods 2016 Oct;13(10):823-7) that describes five conceptual pillars for validating antibodies in an application – and context-specific manner. This pillar requires that antibody-independent and antibody-dependent assays produce results that are correlative.

Antibody 52

Antibody Protein Reagent Scientist 52

The Pharma Data

JANUARY 31, 2021

Utilizing Clover’s proprietary Trimer-Tag© technology, S-Trimer is a trimeric SARS-CoV-2 spike (S)-protein subunit vaccine candidate. About Trimer-Tag© Technology. Trimer-Tag© is an innovative drug development platform which allows the production of novel, covalently-trimerized fusion proteins. . EMERYVILLE, Calif.

Vaccination 52

Vaccination Vaccine Trials Protein 52

Pharmaceutical Technology

MAY 15, 2023

Innovation S-curve for the pharmaceutical industry Peptide nano-particle conjugates is a key innovation area in the pharmaceutical industry By tagging peptides with nanoparticles, peptide nano-particle conjugates allow enhanced control over their biological behaviour, overcoming intrinsic limitations of the individual materials.

Antibody 130

Antibody DNA Development Vaccination 130

pharmaphorum

NOVEMBER 19, 2020

Because Roche has never applied for Avastin to be used in wet AMD, clinics in the US have had to choose between the peace of mind offered by the regulatory process and Lucentis’ higher price tag, or the unapproved off-label formulation of Avastin at a lower price.

FDA Approval 63

FDA Approval Marketing Drugs Clinical Development 63

Delveinsight

FEBRUARY 23, 2021

The company develops transformative biologics including vaccines and therapeutics for the world’s most debilitating diseases. The company plans to use the capital to expand its pipeline of protein-based vaccines and biologic cancer therapies utilizing its innovative and proprietary Trimer-Tag technology platform.

In-Vitro 52

In-Vitro Vaccination Vaccine Licensing 52

XTalks

JANUARY 28, 2022

Immunocore received Breakthrough Device Designation for Kimmtrak from the FDA in February 2021 followed by acceptance of its Biologics License Application (BLA) several months later by both US and European regulators. Kimmtrak has a price tag of $18,760 per vial, which amounts to a weekly dose.

FDA Approval 98

FDA Approval Development Licensing Licensing 98

Drug Discovery World

FEBRUARY 9, 2023

It also carries a much higher price tag for failure. Fortunately, we are also in the age of artificial intelligence (AI), allowing us to not only uncover novel biological insights, but also seek out treatments against very complex biology more efficiently and with more certainty. This creates two scenarios.

Drugs 52

Drugs Development Big Data Scientist 52

Drug Discovery World

MAY 22, 2023

But are these price tags a barrier to access? CGTs are classified as ‘living drugs’ and are much more complex entities than other biologics. The cost 2022 has not been shy of approvals – Uniqure and CSL’s Haemophilia B drug even nabbed the title of “Most Expensive Drug” at $3.5 million per dose.

Gene Therapy 52

Gene Therapy Gene Drugs Contamination 52

Drug Discovery World

JANUARY 30, 2024

Other Challenges: Limited insurance coverage: Many insurance companies are hesitant to cover CGTs due to their high price tags and limited long-term data. Fostering open innovation and collaboration could help address this issue. Increased clinical data and evidence of cost-effectiveness can improve coverage.

Gene Therapy 71

Gene Therapy Manufacturing Gene Clinical Trials 71

XTalks

NOVEMBER 24, 2022

“Gene therapy for hemophilia has been on the horizon for more than two decades,” said Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research (CBER).

Gene Therapy 52

Gene Therapy Gene FDA Approval Genetics 52

XTalks

JANUARY 19, 2024

At the crux of radiobiological considerations are the 5Rs of radiobiology (listed below), which describe the biological response of cells and tissues to radiation. With radiopharmaceutical therapy, in addition to the physics, the biological targeting, uptake, retention and excretion pathways can vary considerably from patient to patient.

DNA 66

DNA Radiology FDA Approval Development 66

XTalks

SEPTEMBER 27, 2022

The record-breaking price tag of Skysona is not surprising for one-time gene therapies like it. The price tag reflects “the clinical benefit [it] provides as an urgently needed treatment option to slow the progression of neurologic dysfunction in children impacted by progressive, irreversible and fatal rare disease,” Obenshain added.

FDA Approval 52

FDA Approval Gene Therapy Drugs Gene 52

XTalks

AUGUST 17, 2020

To learn more about innovations in the field, Xtalks spoke to Anish Suri, PhD, president and chief scientific officer of Cue Biopharma about the company’s initiatives in the development of immune-based biological compounds for the treatment of cancers and autoimmune diseases. Cell-Based Immunotherapy vs. Immune Biologics.

Protein 98

Protein Engineer Immune Response In-Vivo 98

pharmaphorum

MAY 10, 2022

The two partners have also requested a priority review for the Biologics License Application (BLA) for lecanemab, which if granted by the FDA could result in an approval before the end of the year.

FDA Approval 40

FDA Approval Trials Clinical Trials Clinical Trials 40

The Pharma Data

MARCH 7, 2022

Cas9 binds and uses RNA as an address-tag. The system allows scientists, by synthesizing a specific “address-tag” RNA, to bring Cas9 to a precise location in genome and therefore cut and splice genes at specific sites. Ruohola-Baker and Levy then fused this designed protein with a disabled version of a protein called Cas9.

Protein 52

Protein Gene Genome Genomics 52

Intouch Solutions

APRIL 11, 2024

Pre-Clinical : Deeper comprehension of the impacts and outcomes associated with a particular drug. Clinical : Optimized efficiency, inventory management, and service quality of clinical trials. This iterative process yields several benefits, including: Creating clusters of customers based on actual physician behavior.

Compliance 52

Compliance Marketing Drugs Pharma Companies 52

XTalks

MARCH 22, 2023

One reason innovation costs more today than it did in the early 2000s is because of the rising number of large biologic drugs in development requiring specialized manufacturing conditions. In addition, nearly half of all new drugs launched between 2020 and 2021 came with a price tag of $150,000 per year, or more.

Life Science 97

Life Science Drugs FDA Approval Vaccination 97

World of DTC Marketing

DECEMBER 13, 2021

As cancer survival rates rise, so do the price tags of life-saving treatments. OPENING: American cancer patients spent more than $21 billion on their care in 2019. billion included out-of-pocket costs of $16.22 billion and patient time costs of $4.87 Major cancer studies can’t be replicated .

Drugs 55

Drugs FDA Approval Medicine Containment 55

pharmaphorum

JUNE 8, 2021

Biogen chef executive Michel Vounatsos defended Aduhelm in an open letter on the company’s website, saying that the company has “engaged extensively with health economists, public health experts, and payers about Aduhelm – and we have examined other recent biologic drug innovations.”

Drugs 98

Drugs Marketing FDA Approval Trials 98

XTalks

DECEMBER 21, 2022

The multi-million-dollar price tags are largely attributable to the high R&D and manufacturing costs associated with making a gene therapy, as the raw materials for producing the therapy can be expensive. Currently, CSL Behring’s one-dose Hemophilia B gene therapy Hemgenix holds the title at $3.5 million for a single infusion.

Life Science 52

Life Science Gene Therapy Gene Clinical Trials 52

Drug Discovery World

OCTOBER 21, 2022

As we gain deeper understanding of normal biological processes as well as diseases, researchers and clinicians are increasingly seeking to analyse as many cellular parameters as possible to unravel their complexity. Peer reviewed publications are a good resource to understand expected biological expression levels.

Reagent 52

Reagent Antibody Drugs Protein 52

XTalks

OCTOBER 12, 2022

For ASL MR perfusion, water molecules in arterial blood from a feeder artery are magnetically tagged and tracked until they reach the region of interest. Then, the signal difference in the region of interest between the tagged images and control images can be computed to obtain cerebral blood flow (CBF) values ( Figure 3 ).

Clinical Trials 93

Clinical Trials Clinical Trials Trials Drugs 93

Drug Discovery World

JUNE 14, 2023

We have now our lead product in a Phase I/II study, which is a HER-2 directed tag T cell product for patients with HER-2 positive solid tumours. I’ve been with a company for more than five years now. We’ve been working on the technology for many years. The biology is quite complicated… Can it ever work?

Research 52

Research Engineer In-Vivo Production 52

Pharmaceutical Technology

JUNE 21, 2023

The high price tag may be hard to defend , but with lifetime treatment costs for haemophilia B reaching as high as $23m for some, the single-dose treatment could prove far more cost-effective. Despite the limited market, the price tags of haemophilia make it potentially lucrative. Haemophilia B is a rare condition.

Gene Therapy 246

Gene Therapy Gene Sales Protein 246